Could a simple antenatal package combining micronutritional supplementation with presumptive treatment of infection prevent maternal deaths in sub-Saharan Africa? by Collin, Simon M et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Pregnancy and Childbirth
Open Access Research article
Could a simple antenatal package combining micronutritional 
supplementation with presumptive treatment of infection prevent 
maternal deaths in sub-Saharan Africa?
Simon M Collin*1, Rebecca F Baggaley2, Rudiger Pittrof3 and 
Veronique Filippi2
Address: 1Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, BS8 2PR, UK, 2Department of Epidemiology & Population 
Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK and 3Enfield Town Clinic, Wenlock House, 33 
Eaton Road, Enfield, EN1 1NJ, UK
Email: Simon M Collin* - simon.collin@bristol.ac.uk; Rebecca F Baggaley - rebecca.baggaley@lshtm.ac.uk; 
Rudiger Pittrof - rudiger.pittrof@enfield.nhs.uk; Veronique Filippi - veronique.filippi@lshtm.ac.uk
* Corresponding author    
Abstract
Background: Reducing maternal mortality is a key goal of international development. Our objective was
to determine the potential impact on maternal mortality across sub-Saharan Africa of a combination of
dietary supplementation and presumptive treatment of infection during pregnancy. Our aim was to
demonstrate the importance of antenatal interventions in the fight against maternal mortality, and to
stimulate debate about the design of an effective antenatal care package which could be delivered at the
lowest level of the antenatal health system or at community level.
Methods: We collated evidence for the effectiveness of antenatal interventions from systematic reviews
and controlled trials, and we selected interventions which have demonstrated potential to prevent
maternal deaths. We used a model-based analysis to estimate the total reduction in maternal mortality in
sub-Saharan Africa which could be achieved by combining these interventions into a single package, based
on a WHO systematic review of causes of maternal deaths.
Results: Severe hypertensive disorders, puerperal sepsis and anemia are causes of maternal deaths which
could be prevented to some extent by prophylactic measures during pregnancy. A package of pills
comprising calcium and iron supplements and appropriate anti-microbial and anti-malarial drugs could
reduce maternal mortality in sub-Saharan Africa by 8% (range <1% to 20%). This estimate is based on
Cochrane Review estimates for the effectiveness of daily calcium supplements in reducing the risk of death/
serious morbidity due to hypertensive disorders (RR = 0.80, 95% CI 0.65–0.97), anti-microbial prophylaxis
in reducing the odds of puerperal sepsis/postpartum endometritis (OR = 0.49, 95% CI 0.23–1.06), anti-
malarial prophylaxis in reducing the risk of severe antenatal anemia (RR = 0.62, 95% CI 0.50–0.78), and
iron supplementation in reducing the risk of iron deficiency anemia at term (RR = 0.33, 95% CI 0.16–0.69).
Conclusion: Maternal mortality could be reduced by a combination of micronutrient supplementation
and presumptive treatment of infection during pregnancy. Such an approach could be adopted in resource-
poor settings where visits to antenatal clinics are infrequent and would complement existing Safe
Motherhood activities.
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Background
The Millennium Development Goal of halving maternal
mortality by 2015 is unlikely to be achieved in sub-Saha-
ran Africa, where little or no progress has been reported
[1]. Current strategies to save the lives of pregnant women
rightly focus on skilled birth attendance or emergency
obstetric care [2]. There is no doubt that these strategies
could save many lives. However, it is also clear that such
strategies require health care professionals that the poor-
est countries cannot afford to train or retain in sufficient
numbers over the next decade [3]. More importantly,
these strategies might be insufficient in view of the
increasing proportion of maternal deaths attributable to
infectious disease, particularly in sub-Saharan Africa [4].
The majority of women in developing countries come
into contact with health care workers during pregnancy
through antenatal care [5]. Antenatal care for maternal
health has been marginalised for the last 15 years because
of poor risk scoring predictability [2]. The effectiveness of
various components of antenatal care has been studied,
but the overall potential impact on maternal mortality has
not been estimated, as it has been for neonatal outcomes
[6,7].
In this paper, we ask whether a simple antenatal package
which combines micronutritional supplementation with
presumptive treatment of infection, given through ante-
natal care or taken at home under limited supervision,
could prevent some of the 250,000 maternal deaths which
have been estimated to occur each year in sub-Saharan
Africa [8]. Our objective was to estimate the impact of
such a package on maternal mortality in sub-Saharan
Africa, based on the distribution of the causes of maternal
deaths in the region, and based on evidence for the effec-
tiveness of each component. Our broader aim was to
demonstrate the potential importance of antenatal inter-
ventions in developing countries, and to help define a
simple package which could be provided to women who
access existing antenatal care, but which could also be
delivered via outreach programmes to the 25% of women
who fail to make even one antenatal visit.
Methods
Our study is a model-based analysis, which uses a recent
WHO systematic review of causes of maternal deaths [9].
We also used observational studies, reviews, and baseline
data from controlled trials to estimate the prevalence
among pregnant women in sub-Saharan Africa of aetio-
logical factors such as micronutrient deficiency and infec-
tion associated with reported causes of maternal deaths.
We obtained evidence for the effectiveness of antenatal
interventions with the potential to prevent maternal
deaths due to severe hypertensive disorders, sepsis,
malaria, and iron-deficiency anemia from The Cochrane
Library [10].
We first calculated the crude reduction in all-cause mater-
nal mortality which could be achieved through full
(100%) population coverage of the intervention, com-
pared with existing coverage, by multiplying the efficacy
of the intervention by the proportion of all-cause mater-
nal deaths attributable to the preventable cause. Hence,
the percentage reduction r in maternal mortality due to an
intervention against a particular cause of death is given by
Equation 1.
r = (1 - RR) × p (1)
where RR = risk or odds ratio for cause of death comparing
intervention with no intervention, and p = proportion of
all-cause maternal mortality due to a particular cause of
death. For each cause of death we calculated a range for
the percentage reduction r by substituting into the equa-
tion the upper and lower bounds of the 95% confidence
interval for RR and the upper and lower bounds of the
range of p.
To obtain a point estimate and range for the total reduc-
tion in all-cause maternal mortality, we used a model with
two stages. In the first stage, we re-created the distribution
of RR for the reduction in maternal mortality due to the
intervention for each of cause of death by calculating the
error factor for each RR estimate from the 95% confidence
interval (Equation 2, [11]), and taking the mean of the
error factor estimates calculated using the upper and
lower 95% confidence interval. A normal distribution
using the natural log of RR as the mean, and the standard
error of log(RR) (calculated using the error factor, Equa-
tion 3, [11]) as the variance, was created for each cause of
death (using Berkeley Madonna version 8.3.11, University
of California at Berkeley), and 50,000 values of log(RR)
were selected at random from this distribution and trans-
formed to give 50,000 estimates of RR. Equation 1 was
used to calculate r for each RR estimate.
95%CI(RR) = RR/EF to RR × EF (2)
EF = exp [1.96 × SE(log RR)] (3)
A variable proportion of maternal deaths caused by ane-
mia are attributed to malaria; we selected at random from
a uniform distribution for this proportion, with lower
bound 0% (none of the anemia deaths attributed to P fal-
ciparum infection, representing the few parts of sub-Saha-
ran Africa free of malaria), and upper bound 18% (from
an estimate by Brabin et al, representing holoendemic
areas, [12]). This variation was incorporated into the first
stage of the model. Of the remaining deaths caused by
anemia, a variable proportion are attributed to iron defi-
ciency. Our review of the literature suggested a range of
30–70% for this proportion [12-18]. We incorporated theBMC Pregnancy and Childbirth 2007, 7:6 http://www.biomedcentral.com/1471-2393/7/6
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lowest, middle and highest point of this range into the
second stage of our model, as described in the next para-
graph.
In the second stage, we obtained the overall percentage
reduction in all maternal deaths estimated for the inter-
vention. For each of the 50,000 values of RR that we gen-
erated for the effect on each cause of death, we subtracted
the proportion of deaths prevented due to the interven-
tion for one cause of death before calculating the effect on
the next cause of death; this method takes into account
independent co-morbidity, and does not depend on the
order in which causes of death are chosen [7]. The propor-
tions of deaths prevented at the 2.5th and 97.5th percentile
were used as 95% uncertainty intervals. These calculations
were repeated using the point estimate and the lowest and
highest points of the range of the proportion p of maternal
deaths due to each cause found by the recent WHO sys-
tematic review of causes of maternal deaths [9] to produce
three scenarios. At the lowest end of the range of p, we
used the lowest proportion (30%) of non-malarial ane-
mia deaths attributed to iron deficiency; at the highest end
of the range of p, we used the highest proportion (70%) of
non-malarial anemia deaths attributed to iron deficiency.
Results
We identified severe hypertensive disorders, puerperal
sepsis and anemia as causes of maternal deaths which
could be prevented by micronutrient supplementation
and presumptive treatment of infection during the ante-
natal period. Current evidence for the effectiveness of
antenatal interventions for preventing maternal deaths
due to these causes is summarised in Table 1. We could
not identify any simple prophylactic or nutritional inter-
ventions which have potential to prevent the other causes
of maternal deaths identified by the WHO systematic
review (haemorrhage, obstructed labour, abortion, HIV/
AIDS).
Severe hypertensive disorders
A protective effect of calcium supplementation against
severe hypertensive disorders (pre-eclampsia and eclamp-
sia) has been demonstrated among women who have
insufficient dietary intake of calcium [19]. We found two
studies which reported on dietary calcium intake among
pregnant women in sub-Saharan Africa, and both studies
reported average intakes substantially below the recom-
mended daily allowance for pregnant women of 1200
mg/day [20,21]. In the absence of further studies, we
assumed that low calcium intake (<600 mg/day) was
widespread across sub-Saharan Africa. We applied the
20% (1-RR = 0.03–0.35) reduction in risk of maternal
death/serious morbidity reported by the Cochrane Review
(RR = 0.80, 95% CI 0.65–0.97), corresponding to this
level of calcium intake, to the 3.9–21.9% of maternal
deaths attributed to severe hypertensive disorders, to
obtain a reduction in maternal mortality of 0.1–7.7%,
corresponding to 300–19,200 deaths per year (Table 2).
Puerperal sepsis
The Cochrane Review of anti-microbial prophylaxis dur-
ing pregnancy (2nd and 3rd trimester) gives an odds ratio
for puerperal sepsis/postpartum endometritis among
women selected for poor obstetric history (low birth
weight or stillbirth) of 0.46 (95% CI 0.24–0.89); this
result is based on a single trial in Kenya [22]. Among unse-
lected women the odds ratio is not quite significant (OR =
0.49, 95% CI 0.23–1.06). The result for unselected
women is based on two trials, one conducted in the USA
(OR = 0.68, 95% CI 0.23–2.00) and one conducted in
Kenya (OR = 0.36, 95% CI 0.12–1.06). Applying the 51%
risk reduction (1-RR  = 0.00–0.77) reported in the
Cochrane Review for unselected women to the 6.3–12.6%
of maternal deaths attributed to puerperal sepsis (assum-
ing no adverse effect of the intervention) yields a reduc-
tion in maternal mortality of 0.0–9.7%, corresponding to
0–24,300 deaths per year (Table 2).
Anemia
In our crude calculations, we used the estimate by Brabin
et al that, in malarious areas, malaria would be the under-
lying cause of 18% of maternal deaths due to anemia
(hence 0–2.4% of all maternal deaths) [12]. The remain-
der (0–10.8% of all maternal deaths) would be caused by
nutritional deficiencies (mainly iron deficiency), sickle
cell disease, and infection (mainly intestinal parasites
such as hookworm). Studies suggest that 30–70% of all
maternal anemia is due to iron deficiency [12-17]; hence
iron deficiency would be the underlying cause of 0–7.6%
of all maternal deaths.
Anemia due to malaria
WHO recommends preventive intermittent treatment for
falciparum  malaria [23]. The Cochrane Review of anti-
malarials during pregnancy gives a relative risk for severe
antenatal anemia during first and second pregnancies of
0.62 (95% CI 0.50–0.78) [24]. Applying this 38% risk
reduction (1-RR = 0.22–0.50) to the 0–2.4% of maternal
deaths caused by malaria (assuming that the majority of
deaths occurred among primi- and secundigravid
women) gives a reduction in maternal mortality of 0–
1.2% corresponding to 0–3,000 deaths per year (Table 2).
Anemia due to iron deficiency
WHO recommends routine iron supplementation during
pregnancy [25]. The Cochrane Review of iron supplemen-
tation with or without folic acid during pregnancy gives a
risk ratio for iron deficiency anemia at term (Hb below
110 g/L and at least one additional laboratory indicator)
of 0.33 (95% CI 0.16–0.69) [26]. Applying this 67% riskB
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Table 1: Causes of maternal deaths and evidence for preventive antenatal interventions.
Cause of death Aetiology Antenatal intervention Evidence base Grade*
Severe hypertensive disorders 
(eclampsia and pre-eclampsia)
Dietary calcium deficiency Calcium supplementation "Calcium supplementation appears to almost halve the risk of pre-eclampsia, and to 
reduce the rare occurrence of the composite outcome 'death or serious morbidity"' 
[19].
High
Puerperal Sepsis Genitourinary infection Antibiotics "Antibiotic prophylaxis given during the second or third trimester of pregnancy 
reduces the risk of pre-labour rupture of membranes when given routinely to 
pregnant women. Beneficial effects on birth weight and the risk of postpartum 
endometritis were seen for high-risk women" [22].
Moderate
Dietary vitamin A deficiency Vitamin A supplementation "Further evidence on biologically plausible mechanisms of morbidity reduction such as 
reduced incidence of sepsis and/or reduced markers of inflammation are needed" [60].
Low
Dietary micronutrient 
deficiencies
Multiple micronutrient 
supplementation
One trial in Tanzania showed no additional effect on markers of infection (C-reactive 
protein) compared with iron and folic acid [15].
Low
Anemia P. falciparum infection Anti-malarial drugs "Drugs given routinely for malaria during pregnancy reduce severe antenatal anaemia 
in the mother, and are associated with higher birth weight in the baby and probably 
fewer perinatal deaths. This effect appears to be limited to low parity women" [24].
High
Dietary iron deficiency Iron supplementation "Antenatal supplementation with iron or with iron and folic acid results in a substantial 
reduction in the prevalence of haemoglobin levels below 10 or 10.5 g/L at term or 
near term. Routine daily or weekly antenatal iron or iron plus folic acid 
supplementation may be of benefit, especially where pre-gestational iron deficiency 
and anaemia are prevalent" [26].
Moderate
Dietary vitamin A deficiency Vitamin A supplementation "Further evidence on the effectiveness of adding vitamin A to iron and folic acid for 
treatment of anaemia is needed" [60]. "Vitamin A supplementation programmes to 
reduce anaemia should not be implemented in similar antenatal populations in rural 
sub-Saharan Africa unless evidence emerges of positive benefit on substantive clinical 
outcomes" [61].
Low
Dietary micronutrient 
deficiencies
Multiple micronutrient 
supplementation
When compared with supplementation of two or less micronutrients or no 
supplementation or a placebo, multiple-micronutrient supplementation resulted in a 
statistically significant decrease in maternal anaemia (RR 0.61; CI 0.52 to 0.71). 
However, these differences lost statistical significance when multiple-micronutrient 
supplementation was compared with iron folic acid supplementation alone [64].
Low
Intestinal parasitic infection Anthelmintic/antiprotozoal 
drugs
Trials in Sierra Leone and Nepal showed a positive effect on haemoglobin levels 
[57,59].
Moderate
* GRADE Working Group system [65]BMC Pregnancy and Childbirth 2007, 7:6 http://www.biomedcentral.com/1471-2393/7/6
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reduction (1-RR = 0.31–0.84) to the 0–7.6% of maternal
deaths caused by severe iron deficiency anemia gives a
reduction in maternal mortality of 0–6.4% corresponding
to 0–15,900 deaths per year (Table 2).
All causes
Using a range of 0–18% for the proportion of anemia due
to malaria and a range of 30–70% for the proportion of
non-malarial anemia due to iron deficiency in our sce-
nario analysis, our model generated distributions for the
overall reduction in maternal deaths with median values
3.9%, 7.7% and 15.6%, and 95% uncertainty intervals of
0.4–5.7%, 2.4–10.7%, and 8.3–20.3% for the lower
bound, point estimate and upper bound respectively of
the proportion of maternal deaths due to each cause from
the WHO systematic review (Table 3). Hence our overall
estimate for the proportion of maternal deaths prevented
is 8%, with a range of <1–20%, corresponding to 19,300
(range 900–50,800) maternal deaths prevented per year
in sub-Saharan Africa.
Discussion
Our study suggests that a substantial number of maternal
deaths could be prevented in sub-Saharan Africa by nutri-
tional and anti-infection interventions in pregnancy. The
range of our estimate derives from uncertainty about the
causes of maternal deaths, and uncertainty about the
effectiveness of antenatal interventions. We question why
there is so little emphasis on the potential of these antena-
tal strategies by the international safe motherhood com-
munity, and why the initiative has been left to vertical
programmes, such as malaria treatment and prevention.
Of course, we recognize that there is no 'silver bullet' strat-
egy for addressing the effects of a lifetime of undernutri-
tion and infection on maternal health. However, we
believe that any evidence-based intervention which could
be made available to women within the constraints of
existing health infrastructure or through a community-
based outreach approach merits further exploration.
Table 3: Estimated reduction in all-cause maternal mortality due to micronutritional supplementation and presumptive treatment of 
infection.
Lowest estimate Point estimate Highest estimate
Proportion of maternal mortality due to1:
Pre-eclampsia/eclampsia 3.9 9.1 21.9
Puerperal sepsis 6.3 9.7 12.6
Anaemia (all causes) 0.0 3.7 13.2
Proportion of non-malarial anaemia due to iron deficiency2 30% 50% 70%
Percentage reduction in all-cause maternal mortality, median (uncertainty 
interval)
3.9% (0.4–5.7) 7.7% (2.4–10.7) 15.6% (8.3–20.3)
Number of maternal deaths prevented per year, median (uncertainty 
interval)
9,800 (900–14,200) 19,300 (6000–26,600) 38,900 (20,700–50,800)
1 Source: WHO systematic review of causes of maternal deaths [9]
2 Source: references [12-17].
Table 2: Estimated crude reduction in maternal mortality due to micronutritional supplementation and presumptive treatment of 
infection, by cause of maternal death.
Cause of maternal 
death
Proportion of all 
maternal deaths 
(range)1
Intervention Effectiveness of 
intervention – reduction in 
deaths by cause (95% CI)2
Crude reduction in 
all-cause maternal 
mortality3
Maternal deaths 
prevented per year4
Severe hypertensive 
disorders
9.1% (3.9–21.9) calcium 
supplementation
20% (3–35) 0.1–7.7% 300–19,200
Puerperal sepsis 9.7% (6.3–12.6) anti-microbial 
prophylaxis
51% (0–77) 0.0–9.7% 0–24,300
Anemia 3.7% (0.0–13.2) anti-malarial 
prophylaxis
38% (22–50) 0.0–1.2%5 0–3,000
iron supplementation 67% (31–84) 0.0–6.4%6 0–15,900
1 Source: WHO systematic review of causes of maternal deaths [9].
2 Source: Cochrane Reviews [19,22,24,26].
3 Calculated using Equation 1.
4 Assuming 250,000 deaths per year in sub-Saharan Africa [8].
5 Assuming 18% of maternal deaths caused by anemia are attributable to P falciparum infection [12].
6 Assuming 30–70% of non-malarial maternal deaths caused by anemia are attributable to iron deficiency [12-17].BMC Pregnancy and Childbirth 2007, 7:6 http://www.biomedcentral.com/1471-2393/7/6
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Limitations
Evidence of effectiveness based on large-scale randomised
controlled trials of unselected or unscreened population
groups in low-income countries was lacking for presump-
tive treatment of genitourinary infections and micronutri-
ent supplements, with the exception of calcium. Evidence
of effectiveness in preventing maternal mortality was lack-
ing for all interventions. Instead we have assumed that
prevention of mortality is in direct proportion to reduced
risk of morbidity. This assumption is more reasonable for
calcium supplementation and anti-malarial prophylaxis,
where there is evidence of effectiveness in preventing
severe morbidity, than for iron supplementation and anti-
microbial prophylaxis, where the evidence of effectiveness
relates to less severe morbidity.
We have taken into account independent comorbidity
between conditions, eg. anemia and infection, malaria
and pre-eclampsia, but not dependent comorbidity, nor
possible interaction between the components, eg.
between iron and calcium, between iron and vitamin A,
and between P falciparum and micronutrient deficiencies
[13,27,28]. We have produced an estimate for sub-Saha-
ran Africa, but the region is homogeneous neither in the
causes of maternal mortality nor in the prevalence of
micronutrient deficiencies and infection. The WHO sys-
tematic review of causes of maternal deaths included one
study from Egypt, but all of the other included studies
were conducted in countries south of the Sahara.
Our estimate of the impact of the combined intervention
is a best-case scenario, based on 100% coverage compared
with whatever coverage existed in the areas where the
mortality studies were conducted. Although it is estimated
that 68% of women across sub-Saharan Africa have at
least one antenatal consultation [5], the actual provision
and use of treatment and prophylaxis at these consulta-
tions is largely unknown, and is unlikely to be homogene-
ous across sub-Saharan Africa. Even if full coverage were
to be achieved among women who currently access ante-
natal care, the impact of the intervention would vary
across the region, and would also be influenced by adher-
ence to supplementation regimens.
We decided that another layer of estimates (of current and
projected coverage) and corresponding calculations
would over-complicate our model. However, it is a fairly
straightforward exercise to calculate the factor by which
the impact of each intervention would be reduced for less
than full coverage. For example, if two-thirds of women
who currently access antenatal care receive iron prophy-
laxis and anti-malarials (hence 45% of all women), and
full coverage is somehow achieved among women who
currently access antenatal care (68% of all women), then
the impact of these two interventions on deaths due to
anemia will be reduced by a factor of 0.4 (68-45/100-45).
The impact of the two new interventions (calcium supple-
mentation and presumptive treatment of genitourinary
infection) will be reduced by a factor of 0.7 (68/100). The
upper bound of our uncertainty interval for the reduction
in maternal deaths will be around 15%.
Severe hypertensive disorders
The Cochrane Review estimate of the effect of calcium
supplementation in reducing maternal mortality due to
severe hypertensive disorders is based almost entirely on
the result of a WHO multi-centre trial conducted among
women with low dietary calcium intake [29]. We have
made the assumption that diets across sub-Saharan Africa
are unlikely to provide the 1200 mg recommended daily
allowance for pregnant women. Mechanisms to ensure
adherence may become an important issue given the
physical size of calcium tablets. This issue is further com-
plicated by the inhibition of iron absorption by calcium
hence there is likely to be a trade-off between the benefits
of each supplement. The WHO trial used three chewable
500 mg tablets, one tablet to be taken three times daily at
meals but three hours away from any iron supplements
[29]. However, in settings where management of pre-
eclampsia/eclampsia is difficult due to lack of resources, a
preventive strategy might be a worthwhile weapon against
maternal deaths due to hypertensive diseases of preg-
nancy.
Studies from Senegal and The Gambia have reported an
increased risk of death due to eclampsia, RR = 3.1 (95% CI
0.8–14.7) and RR = 5.4 (95% CI 1.5–19.3) respectively,
coincident with peak transmission of P falciparum [30,31].
A three-fold increase in the risk of pre-eclampsia in
women presenting with placental parasitemia was also
reported from a hospital-based study in Dakar [32].
Hence treatment of malaria might be expected to prevent
some deaths due to pre-eclampsia/eclampsia [33]. Sup-
plementation with vitamins C and E has been shown to
have no effect on eclampsia, albeit among well-nourished
women [34,35].
Puerperal sepsis
The inclusion of presumptive treatment of genitourinary
infection, and its estimated impact on puerperal sepsis, is
likely to raise concerns about resistance to antibiotics. The
data from Kenya strongly suggested a beneficial effect of
mass anti-microbial treatment in pregnancy where sexu-
ally transmitted infections are highly prevalent [36]. In
the fourteen years since this trial was conducted, new anti-
biotics have become available [37]. Azithromycin, for
example, has demonstrated efficacy against chlamydia,
gonorrhoea, chancroid, incubating syphilis, mycoplasma,
and possibly bacterial vaginosis, and appears to be with-
out teratogenic risk [38-44]. Azithromycin has been usedBMC Pregnancy and Childbirth 2007, 7:6 http://www.biomedcentral.com/1471-2393/7/6
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for mass treatment of other infections, and has demon-
strated efficacy against P falciparum and P vivax [45-47].
Three trials conducted since the Cochrane review have
provided further evidence, at least for perinatal outcomes,
of the benefits of prophylactic antibiotics in pregnancy
[48].
WHO currently recommends a range of anti-microbials
for treatment of genitourinary infections during preg-
nancy, some prescribed over several days [25]. It is widely
acknowledged that current strategies for treating geni-
tourinary infection among pregnant women in sub-Saha-
ran Africa are failing, and that new approaches are needed
[49-52]. A successful strategy could also contribute to the
prevention of HIV transmission [53]. However, because of
the likely controversy, we would advocate for a large-scale
trial to establish the efficacy and safety of this strategy in
settings where the prevalence of sexually transmitted
infections is high.
Anemia
We have based our estimate on the effects of anti-malarial
treatment and iron supplementation. Although the bene-
fits of intermittent presumptive treatment (IPT) are great-
est among women of low parity, it has been suggested that
IPT should be provided to all pregnant women in areas of
high HIV prevalence because HIV-positive multigravidae
are at similar risk of severe malaria as HIV-positive primi-
gravidae [54].
Nutritional deficiencies are compounded by other infec-
tions, principally hookworm [55-57]. Pathogens such as
Helicobacter pylori may also play a major role [58]. Some
of the maternal deaths caused by anemia, which were
attributable neither to malaria nor to iron deficiency,
might be prevented through a combination of multiple
micronutrient supplementation and presumptive treat-
ment of parasitic and bacterial infection [55,59]. Albenda-
zole has been shown to reduce the decline in
haemoglobin during pregnancy, but there is no conclu-
sive evidence for an effect of vitamin A or other micronu-
trients on anemia during pregnancy, particularly when
compared with iron and folate supplementation [60,61].
Other benefits
Each component of the combined intervention would
benefit neonatal health and survival [7]. Presumptive
treatment of sexually transmitted infections would act
directly to prevent perinatal deaths due to syphilis and
sepsis; treatment and prevention of maternal anemia,
malaria and pre-eclampsia/eclampsia would act indirectly
via higher birth weights and fewer preterm births.
Delivery and cost-effectiveness
The interventions could be combined in a package
designed to facilitate distribution by health providers and
to maximise adherence by patients. Delivery of such a
package need not be confined to health facilities and
could be distributed by community health workers and
others involved in community outreach programmes. Ide-
ally, the package would be implemented in conjunction
with measures to improve access to family planning,
skilled attendance and essential obstetric care.
Studies of the cost-effectiveness of several of the interven-
tions, particularly with regard to neonatal outcomes, sug-
gest that a combined intervention is likely to be cost-
effective in averting maternal and neonatal mortality and
morbidity [7,62,63]. However, considerable gaps in our
knowledge remain, particularly with regard to cost-effec-
tiveness of micronutritional supplementation, and further
research is required. Such research would need to consider
targeted delivery to high-risk groups such as primiparous
women, screening as an alternative to presumptive treat-
ment, and the relative cost-effectiveness of other maternal
health interventions such as provision of essential obstet-
ric care.
Recommendations
Our study is a type of sensitivity analysis, based on the
available evidence. Although the point estimates for the
effectiveness of the constituent interventions could be
debated, the strength of evidence for each manifests as the
upper and lower bounds of the 95% confidence intervals.
These uncertainties combine with the ranges for the
causes of death and underlying prevalence of micronutri-
ent deficiencies and infection, to generate the uncertainty
interval for our final estimate (<1% to 20%). The lower
and upper bounds of this interval almost certainly under-
and over-estimate the impact of combined nutritional
and anti-infection interventions during pregnancy. A nar-
rower interval could be obtained through the gradual
accumulation of evidence from studies and trials, and per-
haps a more sophisticated model. However, we would
argue that there is sufficient evidence for each interven-
tion to support a large cluster randomised controlled trial
of a package combining these interventions, compared
with implementation of current WHO guidelines for ante-
natal care. The intervention and comparison groups could
each have two arms: one based on the prevalent (presum-
ably facility-based) model of antenatal care; the other pro-
viding an enhanced model of antenatal care comprising
facility-based and community outreach teams.
Conclusion
Our estimate for the reduction in the maternal mortality
ratio which could be achieved through a package combin-
ing routine multiple micronutrient supplementation withBMC Pregnancy and Childbirth 2007, 7:6 http://www.biomedcentral.com/1471-2393/7/6
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presumptive treatment of parasitic and bacterial infection
is 8% (range <1–20%). Such a package would comple-
ment the Safe Motherhood measures of skilled birth
attendance, emergency obstetric care and family planning.
We trust that the model which we have presented will
serve to inform the debate over prioritisation of resources
and to highlight the number of maternal deaths which
could be prevented through the relatively simple measure
of implementing and building upon existing antenatal
care recommendations.
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